Preclinical News and Research

RSS

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

SRI International has been awarded a five-year contract valued up to $9.75 million from the National Institute on Drug Abuse to conduct preclinical safety studies of potential new medications to treat substance abuse. SRI researchers will study potential drug-drug interactions between new treatment therapies and common drugs of abuse to assess potential adverse reactions.

6 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy.

5 Nov 2013

Stem cell therapy after traumatic brain injury promotes lasting cognitive improvement

A stem cell therapy previously shown to reduce inflammation in the critical time window after traumatic brain injury also promotes lasting cognitive improvement, according to preclinical research led by Charles Cox, M.D., at The University of Texas Health Science Center at Houston (UTHealth) Medical School.

4 Nov 2013

SRI to expand current preclinical molecular imaging capabilities with MILabs VECTor+ system

MILabs is pleased to announce that Sunnybrook Research Institute, the research arm of the Sunnybrook Health Sciences Centre, located in Toronto, Canada will install a MILabs VECTor+ system to expand their current preclinical molecular imaging capabilities.

4 Nov 2013

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Crown serves pharmaceutical companies and biotech companies. We have two areas of focus: oncology and metabolic diseases. In the oncology space we focus on pre-clinical services. Essentially, we have all the tools to help our customers move from target discovery, target validation, to a clinical candidate.

31 Oct 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013

Mediterranean diet exerts greater cardioprotective effect than low-fat diet, shows study

The Nutrition and Obesity Research Group of the UPV/EHU-University of the Basque Country is studying the effects of diet composition on people's body weight and health. Its participation in the PREDIMED project features among the many pieces of research it has conducted.

30 Oct 2013

Researchers identify new drug for treating irritable bowel syndrome with constipation

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

30 Oct 2013

Middle Peak Medical raises additional $3M in Series A financing

Middle Peak Medical, a development-stage medical device company that will commercialize a novel technology for treating mitral valve disease, has raised an additional $3M in a second closing of its over-subscribed Series A financing, which now totals approximately $11M.

28 Oct 2013

Cancer imaging centers receive £35M grant to develop cutting edge imaging technologies

Cancer imaging is set to get a major boost from a -35 million nationwide initiative to develop cutting edge imaging technologies for basic and clinical cancer research.

25 Oct 2013

Biolinerx Inks In-License Agreement With Israeli Institutions For Type 1 Diabetes Treatment

...

24 Oct 2013

Neuropsychoanalysis Association to host conference on depression

The Neuropsychoanalysis Association is hosting a conference for researchers and clinicians on depression, "Towards a Real Understanding of Depression: Lessons from the Treatment Battlefeld and New Research," on Friday, November 1, 2013 from 9:00 am to 6:00 pm at the Icahn School of Medicine at Mount Sinai, The Bonnie and Kenneth Davis Auditorium, 1470 Madison Avenue (between 101st and 102nd Streets) in New York City.

24 Oct 2013

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

24 Oct 2013

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

...

23 Oct 2013

Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

...

23 Oct 2013

Tissue-engineered transplants safe and effective in the long term: Study

New results published in The Lancet today [Wednesday 23 October] reveal that five years after the first successful transplantation of a tissue-engineered airway (reported in The Lancet in 2008) the recipient continues to enjoy a good quality of life, and has not experienced any immunological complications or rejection of the implanted airway.

23 Oct 2013

Preclinical News and Research

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

Furiex reports financial and operating results for third quarter 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Stem cell therapy after traumatic brain injury promotes lasting cognitive improvement

SRI to expand current preclinical molecular imaging capabilities with MILabs VECTor+ system

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Viropharma announces financial results for third quarter 2013

Mediterranean diet exerts greater cardioprotective effect than low-fat diet, shows study

Researchers identify new drug for treating irritable bowel syndrome with constipation

Middle Peak Medical raises additional $3M in Series A financing

Cancer imaging centers receive £35M grant to develop cutting edge imaging technologies

Biolinerx Inks In-License Agreement With Israeli Institutions For Type 1 Diabetes Treatment

Neuropsychoanalysis Association to host conference on depression

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

Cleveland Biolabs Subsidiary Awarded $4.6M Russian Contract

Tissue-engineered transplants safe and effective in the long term: Study

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics